Oncofocus Test Kit
includes suggestions for Vismodegib
Oncofocus is the world’s most comprehensive precision oncology test that precisely identifies the right drug for your cancer thereby increasing your chances of successful treatment.Discover Oncofocus Today Do you want to order now? Request a test.
Erivedge (vismodegib) is an inhibitor of the hedgehog (Hh) signaling pathway. The pathway promotes cellular development and division in several cell types, both through direct cellular activation and through secondary activation of multiple pathways of tissue generation, including angiogenesis and tissue growth. The pathway is typically over-activated in basal cell carcinoma.
Erivedge is specifically approved for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.
Erivedge is supplied as a tablet for oral administration. The recommended initial dose of Erivedge is 150 mg taken orally once daily until disease progression or until unacceptable toxicity. If a dose of Erivedge is missed, do not make up that dose; resume dosing with the next scheduled dose.
The FDA approval of Erivedge was based on an international, single-arm, multi-center, open-label, two-cohort trial. The trial enrolled 104 subjects with either metastatic basal cell carcinoma (mBCC) or locally advanced BCC (laBCC). The subjects received 150 mg vismodegib per day orally until disease progression or unacceptable toxicity. The median duration of treatment was 10.2 months. The major efficacy outcome measure of the trial was objective response rate (ORR). In the mBCC cohort, tumor response was assessed according to RECIST criteria. In the laBCC cohort, tumor response evaluation included measurement of externally assessable tumor (including scar) and assessment for ulceration in photographs, radiographic assessment of target lesions (if appropriate), and tumor biopsy. Of the 104 subjects enrolled, 96 were evaluable for ORR. In the mBCC cohort, 30.3% reported an ORR and in the laBCC cohort 42.9% reported an ORR. The median response duration in both arms was 7.6 months.
Adverse events associated with the use of Erivedge may include, but are not limited to, the following:
- muscle spasms
- weight loss
- decreased appetite
MECHANISM OF ACTION
Erivedge (vismodegib) is an inhibitor of the hedgehog (Hh) signaling pathway. Vismodegib binds to and inhibits Smoothened, a transmembrane protein involved in Hedgehog signal transduction. The Hh pathway promotes cellular development and division in several cell types, both through direct cellular activation and through secondary acivation of multiple pathways of tissue generation, including angiogenesis and tissue growth. The pathway is typically over-activated in basal cell carcinoma through downregulation of Hedgehog inhibition.